{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-080568","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.118920+00:00","generated_at":"2026-05-20T02:09:54.895265+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Perspective Therapeutics unveils updated corporate presentation with clinical progress","bullets":["Updated presentation highlights [212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors with sustained anti-tumor activity and tolerability.","Melanoma program [212Pb]VMT01 Phase 1/2a trial for metastatic melanoma includes TEAE safety data and trial design.","PSV359 Phase 1/2a trial targets FAP-α expression on tumor and stroma for multiple cancers.","Company describes pre-targeting platform and on-demand supply chain for regional radiopharmaceutical delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-080568","json":"https://secwatch.observer/filing/0000950170-25-080568.json","markdown":"https://secwatch.observer/filing/0000950170-25-080568.md","text":"https://secwatch.observer/filing/0000950170-25-080568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025080568/0000950170-25-080568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025080568/catx-20250603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:09:54.895265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}